CombiGene has entered into an exclusive collaboration and licensing agreement with Spark Therapeutics regarding CG01, CombiGene's gene therapy developed for the treatment of drug-resistant focal epilepsy. Under the terms of the agreement, CombiGene is eligible to receive up to USD 328.5 million excluding royalties, with USD 8.5 million upon signing, as well as up to USD 50 million at several preclinical and clinical milestones.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.26 SEK | -6.59% | -4.40% | +21.19% |
May. 27 | CombiGene Appoints New Chief Scientific Officer | MT |
May. 27 | Combigene AB Appoints Annika Ericsson as New Chief Scientific Officer | CI |
1st Jan change | Capi. | |
---|---|---|
+21.19% | 6.56M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.26% | 21.96B | |
-8.63% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- COMBI Stock
- News CombiGene AB
- CombiGene in Billion-Dollar Deal with Spark Therapeutics